Trial Profile

A Phase II Study to Evaluate the Safety and Efficacy of OQL011 on VEGFR Inhibitor-Associated Hand-Foot Skin Reaction in Cancer Patients

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 07 Mar 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs OQL 011 (Primary)
Indications Erythrodysaesthesia; Skin disorders
Focus Proof of concept; Therapeutic Use
Acronyms NOVA-II
Sponsors OnQuality Pharmaceuticals

Most Recent Events

01 Mar 2024 Planned End Date changed from 1 Mar 2024 to 1 Jun 2024.
01 Mar 2024 Status changed from recruiting to active, no longer recruiting.
06 Apr 2023 Planned End Date changed from 1 Oct 2023 to 1 Mar 2024.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com